Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided.
Type:
Grant
Filed:
February 12, 2016
Date of Patent:
July 31, 2018
Assignee:
MedImmune Limited
Inventors:
Tim Beaumont, Adrianus Q. Bakker, Etsuko Yasuda
Abstract: Humanized anti-Tn-MUC1 antibodies and conjugates thereof. Conjugates comprising pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker to the antibody are described.
Abstract: Respiratory Syncytial Virus is a common cold virus belonging to the family of paramyxovirus. RSV is virulent, easily transmissible and the most common cause of lower respiratory tract disease in children of less than 2 years of age. Up to 98% of children attending day care will be infected in a single RSV season. Between 0.5% and 3.2% of children with RSV infection require hospitalization. Approximately 90,000 hospital admissions and 4500 deaths per year were reported in United States. Major risk factors for hospitalization due to RSV are premature birth, chronic lung disease, congenital heart disease, compromised immunity, and age younger than 6 weeks in otherwise healthy children.
Abstract: Conjugates of specific PBD dimers with an antibody that binds to PSMA, the antibody comprising a VH domain having the sequence according to any one of SEQ ID NOs. 1, 3, 5, 7, 8, 9, or 10, optionally further comprising a VL domain having the sequence 5 according to any one of SEQ ID NOs. 2, 4, 6, 11, 12, 13, 14, 15, 16, 17, or 18.
Type:
Grant
Filed:
October 10, 2014
Date of Patent:
July 3, 2018
Assignee:
Medimmune Limited
Inventors:
Philip Wilson Howard, Patricius Hendrikus Cornelis Van Berkel
Abstract: Provided are polypeptides comprising a variant IgG Fc domain, wherein the polypeptides exhibit reduced or ablated effector functions (e.g., ADCC and/or CDC) and increased stability and plasma half-life compared to a parent polypeptide. Also provided are compositions, methods of treatment, and methods to diminish Fc-induced effector function in a parent polypeptide.
Type:
Grant
Filed:
April 17, 2013
Date of Patent:
July 3, 2018
Assignee:
MedImmune, LLC
Inventors:
Ping Tsui, Martin Borrok, II, William Dall'Acqua
Abstract: Disclosed herein is a method for producing a recombinant polypeptide in a mammalian cell culture in which the mammalian cells have a modified microRNA activity level. In one embodiment, a microRNA activity level is increased. In another embodiment, a microRNA activity level is decreased. In a more particular embodiment, the mammalian cells have a reduced miRNA-let-7a activity level.
Type:
Grant
Filed:
March 12, 2014
Date of Patent:
June 26, 2018
Assignee:
MedImmune, LLC
Inventors:
Katie Streicher, Jonathan Jacobs, Robert W. Georgantas, III, Lydia Greenlees, Koustubh Ranade, Michael Bowen
Abstract: This disclosure relates to anti-Siglec-15 antibodies and uses thereof, in particular in the treatment of leukaemia, such as acute myeloid leukaemia.
Abstract: There are provided pyrrolysine analogs of the formulae (X), (I), (II), (V), (VI), (VII) and (VIII), in which the a, b, d, X, Y, Z, FG, R, R1, R2 and R3 are as defined in the claims, which are useful in bioconjugation processes and mutant proteins containing them.
Type:
Grant
Filed:
August 4, 2014
Date of Patent:
May 29, 2018
Assignee:
MedImmune Limited
Inventors:
Marcello Marelli, Michael van Brunt, Kenneth H. Grabstein
Abstract: The present invention provides therapeutic combinations featuring anti-CD73 antibodies (e.g., MED19447) and A2A receptor inhibitors and methods of using such combinations for reducing tumor-mediated immunosuppression.
Type:
Application
Filed:
September 25, 2017
Publication date:
May 10, 2018
Applicant:
MedImmune Limited
Inventors:
Kris SACHSENMEIER, Erin SULT, Carl HAY, Edmund POON
Abstract: Conjugates of specific PBD dimers with an antibody that binds to CD22, the antibody comprising a VH domain having the sequence according to SEQ ID NO. 1.
Type:
Grant
Filed:
October 10, 2014
Date of Patent:
May 1, 2018
Assignee:
Medimmune Limited
Inventors:
Philip Wilson Howard, Patricius Hendrikus Cornelis Van Berkel
Abstract: Fusion proteins containing B7-H4 polypeptides are disclosed. The B7-H4 fusion proteins can include full-length B7-H4 polypeptides, or can contain a fragment of a full-length B7-H4 polypeptide, including some or all of the extracellular domain of the B7-H4 polypeptide. Methods for using the fusion proteins to downregulate T cell activation and for the treatment of inflammatory and autoimmune diseases and disorders are also disclosed. The B7-H4 fusion proteins are useful for treating inflammation by inhibiting or reducing differentiation, proliferation, activity, and/or cytokine production and/or secretion by ThI, ThI 7, Th22, and/or other cells that secrete, or cause other cells to secrete, inflammatory molecules, including, but not limited to, IL-1?, TNF-?, TGF-beta, IFN-?, IL-17, IL-6, IL-23, IL-22, IL-21, and MMPs; or enhancing IL-IO secretion by Tregs, increasing the differentiation of Tregs, increasing the number of Tregs, or combinations thereof.
Type:
Grant
Filed:
April 6, 2015
Date of Patent:
May 1, 2018
Assignee:
MedImmune, LLC
Inventors:
Solomon Langermann, Linda Liu, Joseph R. Podojil, Stephen D. Miller, Shannon Marshall
Abstract: Conjugates of specific PBD dimers with an antibody that that binds to CD19, the antibody comprising a VH domain having the sequence according to any one of SEQ ID NOs. 1, 2, 3, 4, 5 or 6, optionally further comprising a VL domain having the sequence according to any one of SEQ ID NOs. 7, 8, 9, 10, 11 or 12.
Type:
Grant
Filed:
October 10, 2014
Date of Patent:
April 24, 2018
Assignee:
Medimmune Limited
Inventors:
Philip Wilson Howard, Patricius Hendrikus Cornelis Van Berkel
Abstract: The present invention provides methods of preparing active immunoconjugates, including anti-CD22 immunoconjugates. Suitably, the methods include a fed-batch refolding process and/or column stripping process that result in an increase in yield of the immunoconjugate over other processes that do not utilize the methods.
Type:
Grant
Filed:
December 19, 2013
Date of Patent:
March 20, 2018
Assignee:
MedImmune, LLC
Inventors:
Alan Hunter, Thomas Linke, Timothy Pabst, Michaela Wendeler, Xiangyang Wang, Christopher Thompson, Guoling Xi, Andrew Fulton
Abstract: The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.
Type:
Grant
Filed:
July 13, 2015
Date of Patent:
March 13, 2018
Assignee:
MedImmune, LLC
Inventors:
Guillermo Tous, Mark Schenerman, Jose Casas-Finet, Ziping Wei, David Pfarr
Abstract: The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.
Type:
Grant
Filed:
October 8, 2014
Date of Patent:
February 20, 2018
Assignee:
MedImmune, LLC
Inventors:
Melissa Damschroder, Peter Kiener, Herren Wu, William Dall'Acqua, Ronald Herbst, Anthony Coyle
Abstract: Variants of cytotoxic T-lymphocyte antigen 4 (CTLA-4) with high affinity, potency and stability. Formulations of CTLA-4 variants at high concentration for subcutaneous or intravenous administration, e.g. at monthly or less frequent dosage intervals. Use of CTLA-4 variants for treating rheumatoid arthritis and other inflammatory disorders. Fusion of CTLA-4 with IgG Fc having improved stability and longer in vivo half-life.
Type:
Grant
Filed:
March 11, 2013
Date of Patent:
February 6, 2018
Assignee:
MedImmune Limited
Inventors:
Ralph Minter, Julie Douthwaite, Jacques Moisan, Michael Bowen, Steven Rust, Cyril Privezentzev